Bolt Biotherapeutics Q2 2024 loss from operations $22.6M; cash $97.5M, BDC-3042 advances to Cohort 6

Bolt Biotherapeutics, Inc.

2024-Q2 EPS reported -$0.84 revenue$6,549,000

Loss from operations of $22.6M for Q2 2024 vs $19.8M in Q2 2023; restructuring charges of $3.6M.
Cash, cash equivalents and marketable securities of $97.5M as of June 30, 2024; runway through mid-2026.
BDC-3042 Phase 1 advanced to Cohort 6; no dose-limiting toxicities in Cohort 5.
BDC-4182 (claudin 18.2-targeting ISAC) abstract accepted at SITC 2024; IND-enabling activities ongoing.
Collaboration revenue $1.3M; R&D expenses $15.4M; G&A expenses $4.9M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.